Compare BGC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGC | ACAD |
|---|---|---|
| Founded | 1945 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.4B |
| IPO Year | 1999 | 2004 |
| Metric | BGC | ACAD |
|---|---|---|
| Price | $9.46 | $23.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 22 |
| Target Price | $14.50 | ★ $29.95 |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 02-12-2026 | 02-25-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | 36.46 | ★ 98.53 |
| EPS | 0.33 | ★ 1.54 |
| Revenue | ★ $2,640,884,000.00 | $1,047,118,000.00 |
| Revenue This Year | $36.53 | $15.16 |
| Revenue Next Year | $11.33 | $11.24 |
| P/E Ratio | $27.14 | ★ $15.29 |
| Revenue Growth | ★ 24.59 | 12.69 |
| 52 Week Low | $7.24 | $13.40 |
| 52 Week High | $10.96 | $28.35 |
| Indicator | BGC | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 61.25 | 32.29 |
| Support Level | $8.81 | $23.37 |
| Resistance Level | $9.18 | $26.23 |
| Average True Range (ATR) | 0.29 | 1.00 |
| MACD | 0.02 | -0.37 |
| Stochastic Oscillator | 88.89 | 2.82 |
BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.